IC
FBRX icon

Ikarian Capital’s Forte Biosciences FBRX Stock Holding History

Ikarian Capital’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.08M Sell
118,972
-181,028
-60% -$5.22M 0.25% 81
2025
Q4 		$8.18M Hold
300,000
– – 0.64% 45
2025
Q3 		$4.5M Sell
300,000
-176,443
-37% -$2.03M 0.45% 58
2025
Q2 		$6.16M Sell
476,443
-132,782
-22% -$1.14M 1.18% 30
2025
Q1 		$4.73M Hold
609,225
– – 0.58% 39
2024
Q4 		$13.8M Buy
+609,225
New +$7.25M 1.88% 10

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Ikarian Capital's FBRX Position: Q1 2026 in Review

Ikarian Capital reduced its Forte Biosciences (FBRX) stake by 60% in Q1 2026, selling an estimated $5.22M and leaving 118,972 shares worth $3.08M. The position accounts for 0.25% of the portfolio, ranked #81.

Ikarian Capital first reported a position in FBRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $13.8M in Q4 2024. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Ikarian Capital held 118,972 shares of Forte Biosciences worth $3.08M as of Q1 2026.
  • Ikarian Capital sold 181,028 Forte Biosciences shares in Q1 2026, an estimated $5.22M.
  • Forte Biosciences made up 0.25% of Ikarian Capital's portfolio in Q1 2026, its #81 holding.
  • Ikarian Capital first reported a position in Forte Biosciences in Q4 2024 and has held it in 6 quarters since.
  • Ikarian Capital's Forte Biosciences position peaked at $13.8M in Q4 2024.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.